This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
GreenLight Biosciences Holdings Future Growth
Future criteria checks 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for GreenLight Biosciences Holdings.
Key information
-1.0%
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | 70.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Jul 2023 |
Recent future growth updates
No updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 22 | -161 | -166 | N/A | 1 |
| 12/31/2023 | N/A | -166 | -177 | N/A | 1 |
| 3/31/2023 | 10 | -157 | -146 | -118 | N/A |
| 12/31/2022 | 7 | -167 | -163 | -137 | N/A |
| 9/30/2022 | 4 | -163 | -164 | -137 | N/A |
| 6/30/2022 | 3 | -154 | -143 | -122 | N/A |
| 3/31/2022 | 2 | -129 | -131 | -120 | N/A |
| 12/31/2021 | 2 | -112 | -107 | -92 | N/A |
| 9/30/2021 | 1 | -86 | -98 | -84 | N/A |
| 6/30/2021 | 2 | -89 | -80 | -68 | N/A |
| 3/31/2021 | 2 | -75 | -70 | -58 | N/A |
| 12/31/2020 | 2 | -53 | -57 | -47 | N/A |
| 12/31/2019 | 3 | -37 | -28 | -26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GRNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GRNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GRNA's revenue (70.7% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: GRNA's revenue (70.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GRNA's Return on Equity is forecast to be high in 3 years time